Press Release Dec 10 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing the receipt of final approvals from the USFDA for Silodosin and Pregabalin capsules. Silodosin capsules are used to treat symptoms of an enlarged prostate, while Pregabalin capsules are indicated for nerve pain. The drugs will be manufactured at the company's facility in Ahmedabad, India. This filing serves to inform the exchange and investors about these significant regulatory approvals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 02 2022
- Press Release Dec 01 2022
- Press Release Nov 28 2022
- Press Release Nov 23 2022
- Press Release Nov 16 2022
Later from Zydus Lifesciences
- Press Release Dec 22 2022
- Loss of Share Certificates
- Press Release Dec 30 2022
- Press Release Jan 06 2023
- Press Release Jan 10 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences